Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

The standard phase II trial design has changed dramatically over the past decade. Randomized phase II studies have essentially become the standard phase II design in oncology for a variety of reasons. The use of these designs is motivated by concerns about the use of historical data to determine if a new agent or regimen shows promise of activity. However, randomized phase II designs come with ...

Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

BACKGROUND The endpoints of progression-free survival (pfs) and time-to-progression (ttp) are frequently used to evaluate the clinical benefit of anticancer drugs. However, the surrogacy of those endpoints for overall survival (os) is not validated in all cancer settings. In the present study, we used a trial-based approach to assess the relationship between median pfs or ttp and median os in c...

Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor.

PURPOSE Gastrointestinal stromal tumor (GIST) is a relatively rare tumor that is treated with targeted therapies in advanced stages. Randomized clinical trials (RCT) often require long follow-up and large sample sizes to evaluate overall survival (OS), the gold-standard measure of treatment efficacy. However, changes in therapy following disease progression may complicate survival assessments. ...

the relationship between immunological markers, disease free survival and overall survival in acute myeloid leukemia in north-west of iran

introduction: acute myeloid leukemia (aml) is a clonal disease characterized by heterogeneous involvement of hematopoietic bone marrow cell populations. in aml patients, a variety of clinical and biologic parameters, including surface markers, have been examinedfor potential value in predicting treatment response and survival. by checking the myeloid, lymphoid and nonspecific markers on the bla...

Joint Modeling of Progression-free Survival and Overall Survival by a Bayesian NICE Model